Loading patent…
AssigneeNew River Pharmaceuticals Inc.
InventorsTravis Mickle, Suma Krishnan, Barney Bishop, Christopher Lauderback, James Moncrief, Rob Oberlender, Thomas Piccariello
Estimating the term…
The present invention describes compounds, compositions and methods of using the same comprising lysine covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders, such as attention deficit hyperactivity disorder (ADHD), ADD, narcolepsy, and obesity. Oral bioavailability of amphetamine is maintained at therapeutically useful doses. At higher doses bioavailability is substantially reduced, thereby providing a method of reducing oral abuse liability. Further, compounds and compositions of the invention decrease the bioavailability of amphetamine by parenteral routes, such as intravenous or intranasal administration, further limiting their abuse liability.
A compound comprising amphetamine covalently attached to a lysine.
A compound comprising amphetamine covalently attached to a single lysine.
A compound consisting essentially of amphetamine covalently attached to a lysine.
A compound consisting of amphetamine covalently attached to a lysine.
A composition comprising amphetamine covalently attached to a lysine and a pharmaceutically acceptable excipient.
A composition consisting essentially of amphetamine covalently attached to a lysine and a pharmaceutically acceptable excipient.
A method for delivering amphetamine which prevents or diminishes euphoria, comprising administering to a patient in need thereof a composition formulated for oral dosage comprising amphetamine covalently attached to a single lysine wherein blood levels of amphetamine maintain a therapeutically effective level but do not result in a euphoric effect.
A method for treating a patient in need of amphetamine comprising providing to a patient a composition comprising amphetamine covalently bound to a lysine.
A method for delivering amphetamine comprising providing a patient with a therapeutically effective amount of amphetamine covalently attached to a single lysine which provides a therapeutically bioequivalent AUC when compared to amphetamine administered alone.
A method for delivering amphetamine comprising administering amphetamine covalently bound to a single lysine wherein the oral bioavailability of amphetamine is reduced at doses above those intended for therapeutic effect as compared to non-conjugated amphetamine at doses containing equimolar amounts of amphetamine.
Dependencies are inferred from the claim text.